Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVX 001

Drug Profile

AVX 001

Alternative Names: AKH-217; AVX-001

Latest Information Update: 14 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avexxin
  • Developer Coegin Pharma
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Phase I/II Actinic keratosis

Most Recent Events

  • 14 Sep 2022 Coegin Pharma plans a phase IIa trial for Basal cell cancer in first-half of 2023 (Topical) (Coegin Pharma pipeline, September 2022)
  • 03 Jan 2022 Coegin Pharma announces intention to submit Clinical trial application for Basal cell cancer (Topical) in Q1 2022 (Coegin Pharma pipeline, January 2022)
  • 25 Oct 2021 Phase-I/II clinical trials in Actinic keratosis (In adults, In the elderly) in Denmark (Topical) in October 2021 (EudraCT2021-000934-32)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top